Determinants of excess mortality following unprotected left main stem percutaneous coronary intervention

Objective For percutaneous coronary intervention (PCI) to the unprotected left main stem (UPLMS), there are limited long-term outcome data. We evaluated 5-year survival for UPLMS PCI cases taking into account background population mortality. Methods A population-based registry of 10 682 cases of chronic stable angina (CSA), non-ST-segment elevation acute coronary syndrome (NSTEACS), ST-segment elevation myocardial infarction with (STEMI+CS) and without cardiogenic shock (STEMI−CS) who received UPLMS PCI from 2005 to 2014 were matched by age, sex, year of procedure and country to death data for the UK populace of 56.6 million people. Relative survival and excess mortality were estimated. Results Over 26 105 person-years follow-up, crude 5-year relative survival was 93.8% for CSA, 73.1% for NSTEACS, 77.5% for STEMI−CS and 28.5% for STEMI+CS. The strongest predictor of excess mortality among CSA was renal failure (EMRR 6.73, 95% CI 4.06 to 11.15), and for NSTEACS and STEMI−CS was preprocedural ventilation (6.25, 5.05 to 7.75 and 6.92, 4.25 to 11.26, respectively). For STEMI+CS, the strongest predictor of excess mortality was preprocedural thrombolysis in myocardial infarction (TIMI) 0 flow (2.78, 1.87 to 4.13), whereas multivessel PCI was associated with improved survival (0.74, 0.61 to 0.90). Conclusions Long-term survival following UPLMS PCI for CSA was high, approached that of the background populace and was significantly predicted by co-morbidity. For NSTEACS and STEMI−CS, the requirement for preprocedural ventilation was the strongest determinant of excess mortality. By contrast, among STEMI+CS, in whom survival was poor, the strongest determinant was preprocedural TIMI flow. Future cardiovascular cohort studies of long-term mortality should consider the impact of non-cardiovascular deaths.

[1]  Deepak L. Bhatt,et al.  Culprit-Only vs. Complete Revascularization During ST-Segment Elevation Myocardial Infarction. , 2015, Progress in cardiovascular diseases.

[2]  L. Køber,et al.  Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3—PRIMULTI): an open-label, randomised controlled trial , 2015, The Lancet.

[3]  C. Gale,et al.  Use of relative survival to evaluate non-ST-elevation myocardial infarction quality of care and clinical outcomes. , 2015, European heart journal. Quality of care & clinical outcomes.

[4]  M. Mack,et al.  Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. , 2014, European heart journal.

[5]  Helmut Baumgartner,et al.  2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[6]  D. Bennett,et al.  Outcomes after emergency percutaneous coronary intervention in patients with unprotected left main stem occlusion: the BCIS national audit of percutaneous coronary intervention 6-year experience. , 2014, JACC. Cardiovascular interventions.

[7]  N. Curzen,et al.  Comparative outcomes after unprotected left main stem percutaneous coronary intervention: a national linked cohort study of 5,065 acute and elective cases from the BCIS Registry (British Cardiovascular Intervention Society). , 2014, JACC. Cardiovascular interventions.

[8]  M. Jeong,et al.  Clinical outcomes and predictors of unprotected left main stem culprit lesions in patients with acute ST segment elevation myocardial infarction , 2014, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[9]  B. Gersh,et al.  Trends in Cause of Death After Percutaneous Coronary Intervention , 2014, Circulation.

[10]  M. Pérez-Vizcayno,et al.  Clinical impact of intravascular ultrasound guidance in drug-eluting stent implantation for unprotected left main coronary disease: pooled analysis at the patient-level of 4 registries. , 2014, JACC. Cardiovascular interventions.

[11]  Sankey V. Williams,et al.  2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Ass , 2012, Journal of the American College of Cardiology.

[12]  Sankey V. Williams,et al.  2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physi , 2012, Circulation.

[13]  Sean M. O'Brien,et al.  Prediction of Long-Term Mortality After Percutaneous Coronary Intervention in Older Adults: Results From the National Cardiovascular Data Registry , 2012, Circulation.

[14]  Helmut Baumgartner,et al.  ESC / EACTS Guidelines on myocardial revascularization , 2014 .

[15]  Maarten L. Simoons,et al.  The third universal definition of myocardial infarction , 2013 .

[16]  P. Ludman British Cardiovascular Intervention Society Registry for audit and quality assessment of percutaneous coronary interventions in the United Kingdom , 2011, Heart.

[17]  G. Stone,et al.  Comparison between the NERS (New Risk Stratification) score and the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) score in outcome prediction for unprotected left main stenting. , 2010, JACC. Cardiovascular interventions.

[18]  M. Coleman,et al.  Modelling relative survival in the presence of incomplete data: a tutorial. , 2010, International journal of epidemiology.

[19]  P. Teirstein,et al.  Revascularization for unprotected left main disease: evolution of the evidence basis to redefine treatment standards. , 2009, Journal of the American College of Cardiology.

[20]  David R. Jones,et al.  Relative survival: what can cardiovascular disease learn from cancer? , 2008, European heart journal.

[21]  J. Estève,et al.  An overall strategy based on regression models to estimate relative survival and model the effects of prognostic factors in cancer survival studies , 2007, Statistics in medicine.

[22]  Paul W Dickman,et al.  Regression models for relative survival , 2004, Statistics in medicine.

[23]  G. Maudsley,et al.  "Inaccuracy' in death certification--where are we now? , 1996, Journal of public health medicine.